Cargando…
Recent advances in the management of Hodgkin lymphoma
Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant dise...
Autores principales: | Villasboas, Jose C., Ansell, Stephen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850875/ https://www.ncbi.nlm.nih.gov/pubmed/27158471 http://dx.doi.org/10.12688/f1000research.8301.1 |
Ejemplares similares
-
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016) -
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
por: Wang, Yucai, et al.
Publicado: (2018) -
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
por: Jalali, Shahrzad, et al.
Publicado: (2019) -
Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017) -
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
por: Feugier, Pierre, et al.
Publicado: (2019)